Cargando…
Optimizing Cardiac Out-Put to Increase Cerebral Penumbral Perfusion in Large Middle Cerebral Artery Ischemic Lesion—OPTIMAL Study
INTRODUCTION: In unsuccessful vessel recanalization, clinical outcome of acute stroke patients depends on early improvement of penumbral perfusion. So far, mean arterial blood pressure (MAP) is the target hemodynamic parameter. However, the correlations of MAP to cardiac output (CO) and cerebral per...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554127/ https://www.ncbi.nlm.nih.gov/pubmed/28848494 http://dx.doi.org/10.3389/fneur.2017.00402 |
_version_ | 1783256728968626176 |
---|---|
author | Fuhrer, Hannah Günther, Albrecht Zinke, Jan Niesen, Wolf-Dirk |
author_facet | Fuhrer, Hannah Günther, Albrecht Zinke, Jan Niesen, Wolf-Dirk |
author_sort | Fuhrer, Hannah |
collection | PubMed |
description | INTRODUCTION: In unsuccessful vessel recanalization, clinical outcome of acute stroke patients depends on early improvement of penumbral perfusion. So far, mean arterial blood pressure (MAP) is the target hemodynamic parameter. However, the correlations of MAP to cardiac output (CO) and cerebral perfusion are volume state dependent. In severe subarachnoid hemorrhage, optimizing CO leads to a reduction of delayed ischemic neurological deficits and improvement of clinical outcome. This study aims to investigate the effect of standard versus advanced cardiac monitoring with optimization of CO on the clinical outcome in patients with large ischemic stroke. METHODS AND ANALYSIS: The OPTIMAL study is a prospective, multicenter, open, into two arms (1:1) randomized, controlled trial. Sample size estimate: sample sizes of 150 for each treatment group (300 in total) ensure an 80% power to detect a difference of 16% of a dichotomized level of functional clinical outcome at 3 months at a significance level of 0.05. Study outcomes: the primary endpoint is the functional outcome at 3 months. The secondary endpoints include functional outcome at 6 months follow-up, and complications related to hemodynamic monitoring and therapies. DISCUSSION: The results of this trial will provide data on the safety and efficacy of advanced hemodynamic monitoring on clinical outcome. ETHICS AND DISSEMINATION: The trial was approved by the leading ethics committee of Freiburg University, Germany (438/14, 2015) and the local ethics committees of the participating centers. The study is performed in accordance with the Declaration of Helsinki and the guidelines of Good Clinical Practice. It is registered in the German Clinical Trial register (DRKS; DRKS00007805). Dissemination will include submission to peer-reviewed professional journals and presentation at congresses. Hemodynamic monitoring may be altered in a specific stroke patient cohort if the study shows that advanced monitoring is safe and improves the functional outcome. |
format | Online Article Text |
id | pubmed-5554127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55541272017-08-28 Optimizing Cardiac Out-Put to Increase Cerebral Penumbral Perfusion in Large Middle Cerebral Artery Ischemic Lesion—OPTIMAL Study Fuhrer, Hannah Günther, Albrecht Zinke, Jan Niesen, Wolf-Dirk Front Neurol Neuroscience INTRODUCTION: In unsuccessful vessel recanalization, clinical outcome of acute stroke patients depends on early improvement of penumbral perfusion. So far, mean arterial blood pressure (MAP) is the target hemodynamic parameter. However, the correlations of MAP to cardiac output (CO) and cerebral perfusion are volume state dependent. In severe subarachnoid hemorrhage, optimizing CO leads to a reduction of delayed ischemic neurological deficits and improvement of clinical outcome. This study aims to investigate the effect of standard versus advanced cardiac monitoring with optimization of CO on the clinical outcome in patients with large ischemic stroke. METHODS AND ANALYSIS: The OPTIMAL study is a prospective, multicenter, open, into two arms (1:1) randomized, controlled trial. Sample size estimate: sample sizes of 150 for each treatment group (300 in total) ensure an 80% power to detect a difference of 16% of a dichotomized level of functional clinical outcome at 3 months at a significance level of 0.05. Study outcomes: the primary endpoint is the functional outcome at 3 months. The secondary endpoints include functional outcome at 6 months follow-up, and complications related to hemodynamic monitoring and therapies. DISCUSSION: The results of this trial will provide data on the safety and efficacy of advanced hemodynamic monitoring on clinical outcome. ETHICS AND DISSEMINATION: The trial was approved by the leading ethics committee of Freiburg University, Germany (438/14, 2015) and the local ethics committees of the participating centers. The study is performed in accordance with the Declaration of Helsinki and the guidelines of Good Clinical Practice. It is registered in the German Clinical Trial register (DRKS; DRKS00007805). Dissemination will include submission to peer-reviewed professional journals and presentation at congresses. Hemodynamic monitoring may be altered in a specific stroke patient cohort if the study shows that advanced monitoring is safe and improves the functional outcome. Frontiers Media S.A. 2017-08-10 /pmc/articles/PMC5554127/ /pubmed/28848494 http://dx.doi.org/10.3389/fneur.2017.00402 Text en Copyright © 2017 Fuhrer, Günther, Zinke and Niesen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Fuhrer, Hannah Günther, Albrecht Zinke, Jan Niesen, Wolf-Dirk Optimizing Cardiac Out-Put to Increase Cerebral Penumbral Perfusion in Large Middle Cerebral Artery Ischemic Lesion—OPTIMAL Study |
title | Optimizing Cardiac Out-Put to Increase Cerebral Penumbral Perfusion in Large Middle Cerebral Artery Ischemic Lesion—OPTIMAL Study |
title_full | Optimizing Cardiac Out-Put to Increase Cerebral Penumbral Perfusion in Large Middle Cerebral Artery Ischemic Lesion—OPTIMAL Study |
title_fullStr | Optimizing Cardiac Out-Put to Increase Cerebral Penumbral Perfusion in Large Middle Cerebral Artery Ischemic Lesion—OPTIMAL Study |
title_full_unstemmed | Optimizing Cardiac Out-Put to Increase Cerebral Penumbral Perfusion in Large Middle Cerebral Artery Ischemic Lesion—OPTIMAL Study |
title_short | Optimizing Cardiac Out-Put to Increase Cerebral Penumbral Perfusion in Large Middle Cerebral Artery Ischemic Lesion—OPTIMAL Study |
title_sort | optimizing cardiac out-put to increase cerebral penumbral perfusion in large middle cerebral artery ischemic lesion—optimal study |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554127/ https://www.ncbi.nlm.nih.gov/pubmed/28848494 http://dx.doi.org/10.3389/fneur.2017.00402 |
work_keys_str_mv | AT fuhrerhannah optimizingcardiacoutputtoincreasecerebralpenumbralperfusioninlargemiddlecerebralarteryischemiclesionoptimalstudy AT guntheralbrecht optimizingcardiacoutputtoincreasecerebralpenumbralperfusioninlargemiddlecerebralarteryischemiclesionoptimalstudy AT zinkejan optimizingcardiacoutputtoincreasecerebralpenumbralperfusioninlargemiddlecerebralarteryischemiclesionoptimalstudy AT niesenwolfdirk optimizingcardiacoutputtoincreasecerebralpenumbralperfusioninlargemiddlecerebralarteryischemiclesionoptimalstudy |